Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.14
QDEL's Cash-to-Debt is ranked lower than
62% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.86 vs. QDEL: 1.14 )
Ranked among companies with meaningful Cash-to-Debt only.
QDEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 1.85 Max: 13.76
Current: 1.14
0.09
13.76
Equity-to-Asset 0.52
QDEL's Equity-to-Asset is ranked lower than
60% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. QDEL: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
QDEL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.77 Max: 0.85
Current: 0.52
0.52
0.85
Piotroski F-Score: 4
Altman Z-Score: 3.27
Beneish M-Score: -2.44
WACC vs ROIC
10.38%
-5.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -2.32
QDEL's Operating Margin % is ranked lower than
55% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. QDEL: -2.32 )
Ranked among companies with meaningful Operating Margin % only.
QDEL' s Operating Margin % Range Over the Past 10 Years
Min: -13.49  Med: 4.48 Max: 31.99
Current: -2.32
-13.49
31.99
Net Margin % -7.21
QDEL's Net Margin % is ranked lower than
56% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. QDEL: -7.21 )
Ranked among companies with meaningful Net Margin % only.
QDEL' s Net Margin % Range Over the Past 10 Years
Min: -9.94  Med: 3.69 Max: 20.02
Current: -7.21
-9.94
20.02
ROE % -6.85
QDEL's ROE % is ranked lower than
55% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. QDEL: -6.85 )
Ranked among companies with meaningful ROE % only.
QDEL' s ROE % Range Over the Past 10 Years
Min: -9.43  Med: 3.04 Max: 26.77
Current: -6.85
-9.43
26.77
ROA % -3.60
QDEL's ROA % is ranked lower than
52% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. QDEL: -3.60 )
Ranked among companies with meaningful ROA % only.
QDEL' s ROA % Range Over the Past 10 Years
Min: -5.92  Med: 2.4 Max: 21.27
Current: -3.6
-5.92
21.27
ROC (Joel Greenblatt) % -5.86
QDEL's ROC (Joel Greenblatt) % is ranked lower than
51% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. QDEL: -5.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
QDEL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -33.25  Med: 11.53 Max: 145.36
Current: -5.86
-33.25
145.36
3-Year Revenue Growth Rate 4.90
QDEL's 3-Year Revenue Growth Rate is ranked higher than
55% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. QDEL: 4.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
QDEL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.1  Med: 6.6 Max: 20.5
Current: 4.9
-5.1
20.5
3-Year EBITDA Growth Rate -13.00
QDEL's 3-Year EBITDA Growth Rate is ranked lower than
73% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. QDEL: -13.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
QDEL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -58.5  Med: -7.8 Max: 245.9
Current: -13
-58.5
245.9
GuruFocus has detected 2 Warning Signs with Quidel Corp $QDEL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» QDEL's 10-Y Financials

Financials (Next Earnings Date: 2017-05-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

QDEL Guru Trades in Q1 2016

Jim Simons 300,500 sh (+44.69%)
Mario Gabelli 624,100 sh (+4.02%)
» More
Q2 2016

QDEL Guru Trades in Q2 2016

Jim Simons 404,700 sh (+34.68%)
Mario Gabelli 626,100 sh (+0.32%)
» More
Q3 2016

QDEL Guru Trades in Q3 2016

Jim Simons 484,300 sh (+19.67%)
Mario Gabelli 626,100 sh (unchged)
» More
Q4 2016

QDEL Guru Trades in Q4 2016

Jim Simons 502,200 sh (+3.70%)
Mario Gabelli 626,100 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with QDEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:HSKA, NAS:NEO, NAS:BEAT, NAS:VIVO, NYSE:ARA, NAS:NRCIA, NAS:NTRA, NAS:ALOG, NAS:LNTH, NAS:NVDQ, NYSE:NVTA, NAS:KANG, NAS:GHDX, NAS:OXFD, NYSE:ENZ, NAS:ONVO, NAS:SRDX, NAS:ABAX, NAS:RDNT, NAS:MEDP » details
Traded in other countries:QL1.Germany,
Quidel Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. It includes applications in infectious diseases, women's health and gastrointestinal diseases.

Quidel Corp is a corporation, originally incorporated as Monoclonal Antibodies, Inc. in California in 1979 and re-incorporated as Quidel Corporation in the State of Delaware in 1987. The Company is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions include applications in infectious diseases, women's health and gastrointestinal diseases. It sells products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. It markets its products in the United States through a network of national and regional distributors, and through a direct sales force. Internationally, it markets through distributor arrangements. The Company commenced its operations in 1979 and launched its first products, dipstick-based pregnancy tests, in 1983. In February 2010, it expanded its operations through the acquisition of Diagnostic Hybrids, Inc., a privately-held, in vitro diagnostics (IVD) company, based in Athens, Ohio. In 2013, it completed two further acquisitions, acquiring BioHelix Corporation, a developer and manufacturer of isothermal molecular assays and enzymes, in May 2013, and acquiring the assets of AnDiaTec GmbH, a German based developer and manufacturer of molecular assays, in August 2013. The Company's customers for IVD products are centralized laboratories and physician offices and decentralized point-of-care settings. It provides diagnostic testing solutions under various brand names, including, among others, - Quidel, QuickVue, QuickVue+, Sofia, AmpliVue, Solana, Virena, MicroVue, Lyra, FreshCells, D3, FastPoint, ReadyCells, Super E-Mix, ELVIRA, ELVIS and Thyretain. The diagnostic testing solutions are provided through a number of proprietary platforms, including Fluorescent Immunoassays; Molecular Assays; Molecular Systems in Development; and Connectivity and Data Management. The products under medical and wellness categories are Infectious Diseases - Influenza, Streptococci, RSV, Multiplex Respiratory, General Virology, Herpes and Herpes Family; POC Women's and General Health - Pregnancy, Graves Disease, Chlamydia, Bone Health; Bone Health, Autoimmune Disease and Oncology; Gastrointestinal Diseases - Clostridium difficile, Enterovirus, Helicobacter pylori, Immunoassay fecal occult blood. The Company has two manufacturing sites in San Diego, California and Athens, Ohio. San Diego facility consists of laboratories devoted to tissue culture, cell culture, protein purification and immunochemistry and production areas dedicated to manufacturing and assembly. Athens facility consists of clean rooms (FS-209E Class 1000: ISO Class 6) for the culturing and dispensing of cell cultures under cGMP conditions. The facility also has laboratories devoted to tissue culture for the production of monoclonal an

Top Ranked Articles about Quidel Corp

Douglas Bryant Sells Quidel Corp The CEO and president sold 69,168 shares
Douglas Bryant (Insider Trades), CEO and president of Quidel Corp. (NASDAQ:QDEL), sold 69,168 shares of the company on Sept. 30. The average price per share was $21.76, for a total transaction of $1,505,096. Quidel, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, has a market cap of $704.21 million. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 30.12
QDEL's Forward PE Ratio is ranked lower than
67% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.83 vs. QDEL: 30.12 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 3.59
QDEL's PB Ratio is ranked higher than
52% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.55 vs. QDEL: 3.59 )
Ranked among companies with meaningful PB Ratio only.
QDEL' s PB Ratio Range Over the Past 10 Years
Min: 2.12  Med: 3.53 Max: 6.72
Current: 3.59
2.12
6.72
PS Ratio 3.72
QDEL's PS Ratio is ranked lower than
56% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. QDEL: 3.72 )
Ranked among companies with meaningful PS Ratio only.
QDEL' s PS Ratio Range Over the Past 10 Years
Min: 1.84  Med: 3.89 Max: 6.17
Current: 3.72
1.84
6.17
Price-to-Operating-Cash-Flow 60.31
QDEL's Price-to-Operating-Cash-Flow is ranked lower than
90% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.21 vs. QDEL: 60.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
QDEL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.39  Med: 20.11 Max: 75.1
Current: 60.31
5.39
75.1
EV-to-EBITDA 38.08
QDEL's EV-to-EBITDA is ranked lower than
87% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.84 vs. QDEL: 38.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
QDEL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -176.9  Med: 18.7 Max: 189.5
Current: 38.08
-176.9
189.5
Shiller PE Ratio 124.34
QDEL's Shiller PE Ratio is ranked lower than
97% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.56 vs. QDEL: 124.34 )
Ranked among companies with meaningful Shiller PE Ratio only.
QDEL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 37.84  Med: 71.61 Max: 154.46
Current: 124.34
37.84
154.46
Current Ratio 6.71
QDEL's Current Ratio is ranked higher than
86% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. QDEL: 6.71 )
Ranked among companies with meaningful Current Ratio only.
QDEL' s Current Ratio Range Over the Past 10 Years
Min: 1.77  Med: 4.15 Max: 7.81
Current: 6.71
1.77
7.81
Quick Ratio 5.93
QDEL's Quick Ratio is ranked higher than
88% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. QDEL: 5.93 )
Ranked among companies with meaningful Quick Ratio only.
QDEL' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 3.37 Max: 6.95
Current: 5.93
1.12
6.95
Days Inventory 123.06
QDEL's Days Inventory is ranked lower than
67% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.88 vs. QDEL: 123.06 )
Ranked among companies with meaningful Days Inventory only.
QDEL' s Days Inventory Range Over the Past 10 Years
Min: 77.63  Med: 103.27 Max: 130.34
Current: 123.06
77.63
130.34
Days Sales Outstanding 47.61
QDEL's Days Sales Outstanding is ranked higher than
70% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.18 vs. QDEL: 47.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
QDEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.59  Med: 54.61 Max: 76.33
Current: 47.61
21.59
76.33
Days Payable 79.78
QDEL's Days Payable is ranked higher than
67% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. QDEL: 79.78 )
Ranked among companies with meaningful Days Payable only.
QDEL' s Days Payable Range Over the Past 10 Years
Min: 29.04  Med: 40.05 Max: 79.78
Current: 79.78
29.04
79.78

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.40
QDEL's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. QDEL: 1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
QDEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.6  Med: -2.7 Max: 4.7
Current: 1.4
-6.6
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 18.83
QDEL's Price-to-Net-Current-Asset-Value is ranked lower than
73% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.22 vs. QDEL: 18.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
QDEL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.45  Med: 10.41 Max: 45.85
Current: 18.83
3.45
45.85
Price-to-Tangible-Book 8.00
QDEL's Price-to-Tangible-Book is ranked lower than
68% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.72 vs. QDEL: 8.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
QDEL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.15  Med: 5.4 Max: 13.03
Current: 8
1.15
13.03
Price-to-Intrinsic-Value-Projected-FCF 2.69
QDEL's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
55% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. QDEL: 2.69 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
QDEL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.06  Med: 2.91 Max: 7.08
Current: 2.69
1.06
7.08
Price-to-Median-PS-Value 0.96
QDEL's Price-to-Median-PS-Value is ranked higher than
58% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. QDEL: 0.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
QDEL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.87 Max: 1.54
Current: 0.96
0.26
1.54
Earnings Yield (Greenblatt) % -0.62
QDEL's Earnings Yield (Greenblatt) % is ranked higher than
53% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.78 vs. QDEL: -0.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
QDEL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.66  Med: 3.6 Max: 17.3
Current: -0.62
-0.66
17.3
Forward Rate of Return (Yacktman) % -7.57
QDEL's Forward Rate of Return (Yacktman) % is ranked lower than
84% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. QDEL: -7.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
QDEL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.1  Med: 2.4 Max: 49.7
Current: -7.57
-9.1
49.7

More Statistics

Revenue (TTM) (Mil) $191.6
EPS (TTM) $ -0.43
Beta1.17
Short Percentage of Float15.90%
52-Week Range $15.15 - 23.94
Shares Outstanding (Mil)32.95

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.72
EPS without NRI ($) 0.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for QDEL

Headlines

Articles On GuruFocus.com
Douglas Bryant Sells Quidel Corp. Oct 03 2016 
Top Insider Buys Highlight: Quidel Corporation Jul 28 2014 
Weekly CEO Buys Highlight: TDY, KOPN, QDEL, SALM, FCAL Mar 24 2012 
CEO Buys 6/10/11: Quidel Corp. Jun 10 2011 
Quidel Corp. Reports Operating Results (10-Q) Oct 29 2010 
Quidel Corp. Reports Operating Results (10-Q) Jul 30 2010 
Quidel Corp. (QDEL) CFO John Matthew Radak buys 1,000 Shares Jun 22 2010 
Quidel Corp. Reports Operating Results (10-Q) May 03 2010 
MFI STOCK REVIEW: QUIDEL CORP (QDEL) Apr 01 2010 
Take Advantage of a 43% Upside on this Healthcare Reform Stock Trade Mar 30 2010 

More From Other Websites
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo Mar 24 2017
OraSure Technologies (OSUR) In Focus: Stock Jumps 8.4% Mar 22 2017
The Zacks Analyst Blog Highlights: Health Insurance Innovations, Big 5 Sporting Goods, Quidel,... Mar 16 2017
Small Caps Back to Breakeven for 2017, Buy These 5 Stocks on the Dip Mar 15 2017
Orthofix International (OFIX) Looks Good: Stock Jumps 9.9% Mar 15 2017
QUIDEL CORP /DE/ Files SEC form 8-K, Regulation FD Disclosure Mar 13 2017
Quidel to Present at the Barclays Global Healthcare Conference Mar 02 2017
QUIDEL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Feb 28 2017
QUIDEL CORP /DE/ Financials Feb 22 2017
QUIDEL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Feb 21 2017
Coverage initiated on Quidel by CL King Feb 17 2017
QUIDEL CORP /DE/ Files SEC form 10-K, Annual Report Feb 16 2017
Quidel Corp. :QDEL-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 Feb 15 2017
Quidel Corp. :QDEL-US: Earnings Analysis: 2016 By the Numbers : February 10, 2017 Feb 10 2017
Edited Transcript of QDEL earnings conference call or presentation 8-Feb-17 10:00pm GMT Feb 08 2017
Quidel reports 4Q loss Feb 08 2017
Quidel reports 4Q loss Feb 08 2017
Quidel Corp Earnings Call scheduled for 5:00 pm ET today Feb 08 2017
QUIDEL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 08 2017
Quidel Reports Fourth Quarter and Full Year 2016 Financial Results Feb 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)